Table 1.
Age (ye- ars) | Sex | Past medi- cal his- tory | Symp- toms | ECG | Peak Tro- ponin (ng/L) | CAD ruled out | Time from 3rd vaccine and symp- toms (days) | Time bet- ween 3rd vaccine and MRI (days) | LVEF % | Wall motion abnorm- ality | LVEDV/ BSA | LVESV/ BSA | LV- mass/ BSA | T1 global (ms) | T1 focal (ms) | T2 global (ms) | T2 focal (ms) | Global ECV (%) | Focal ECV (%) | LGE (%) | LGE local- ization | LGE pat-tern | LGE in peri- card | Peri- car- dial effu- sion | Dia- meter of effu- sion (mm) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | M | None | Chest pain | Infe- rior STE | 240 | CA | 4 | 8 | 53 | Lateral wall | 73.5 | 33.9 | 49.6 | 1,078 ± 107 | 1,135 ± 118 | 62 ± 8 |
69.2 | 30.1 | 36 | 9 | Antero- lateral, infero- lateral (basal, mid) Lateral (apical) |
Epicar- dial and mid-wall |
Y | N | |
44 | F | None | Chest pain | Nor- mal | 80 | CCT | 2 | 40 | 63 | N | 70.6 | 25.8 | 31.7 | 1,039 ± 70 | 1,077 ± 66 | 52.4 ± 6 | 57.5 | 30.5 | 31.9 | 1 | Apex, infero- septal (basal) | Mid-wall | Y | N | |
26 | M | As- thma |
Chest pain | Diff- use STE | 4,967 | N | 14 | 47 | 71 | N | 76.7 | 22.2 | 46.9 | 1,045 ± 93 | 1,155 ± 89 | 50 ± 6.7 | 58.1 | 34.2 | 44.9 | 3 | Inferior and infero- lateral (basal) |
Epicar- dial |
N | Circular | 5 |
18 | M | None | Chest pain | Diff- use STE | 79 | CCT | 3 | 42 | 59 | N | 74 | 31.4 | 45.8 | 1,008 ± 70 | 1,041 ± 80 | 49 ± 4.4 | 57.4 | 27.3 | 29.3 | 1 | Inferior (basal) | Epicar- dial |
N | Circular | 4 |
M, male; Y, yes; N, no; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; ECG, electrocardiogram; LVESV, left ventricular end-systolic volume; BSA, body surface are; LGE, late gadolinium enhancement; CAD, coronary artery disease; CA, coronary angiography; CCT, cardiac computed tomography; STE, ST-segment elevation.